I find it very funny that the wanna-be biotech sto
Post# of 30066
Posted On: 07/10/2014 1:27:48 PM
I find it very funny that the wanna-be biotech stock analyst posting on IHUB can't even get the name of Eli Lilly's Amyvid product right. He continues to refer to it incorrectly as AMVID. Watch that change once he reads this post. LOL
He also believes it to be the current "gold standard" in diagnosing AD in trial participants, a standard which LymPro must overcome. Funny, but Amyvid only indicates the presence of beta amyloid plaques in the brain. These plaques are present in all people with AD, but they are also present in other neurological disorders besides AD. Research continues to try to determine if these plaques are a cause/contributor for the onset of AD, or merely a by-product of having AD.
So while Amyvid is certainly useful in diagnosing patients who do NOT have AD, it is of little use to determine who DOES have AD. Hopefully when the LymPro results are released, it will more adequately fill this role.
From the Eli Lilly document on Amyvid: http://pi.lilly.com/us/amyvid-uspi.pdf
– The IRRELEPHANT –
Posting Irrelevant Nonsense on a Message Board Near You
He also believes it to be the current "gold standard" in diagnosing AD in trial participants, a standard which LymPro must overcome. Funny, but Amyvid only indicates the presence of beta amyloid plaques in the brain. These plaques are present in all people with AD, but they are also present in other neurological disorders besides AD. Research continues to try to determine if these plaques are a cause/contributor for the onset of AD, or merely a by-product of having AD.
So while Amyvid is certainly useful in diagnosing patients who do NOT have AD, it is of little use to determine who DOES have AD. Hopefully when the LymPro results are released, it will more adequately fill this role.
From the Eli Lilly document on Amyvid: http://pi.lilly.com/us/amyvid-uspi.pdf
Quote:
INDICATIONS AND USAGE
Amyvid is a radioactive diagnostic agent for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative Amyvid scan indicates sparse to no neuritic plaques, and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Amyvid scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Amyvid is an adjunct to other diagnostic evaluations.
Limitations of Use
• A positive Amyvid scan does not establish a diagnosis of AD or other cognitive disorder.
• Safety and effectiveness of Amyvid have not been established for:
• Predicting development of dementia or other neurologic condition;
• Monitoring responses to therapies.
– The IRRELEPHANT –
Posting Irrelevant Nonsense on a Message Board Near You
(0)
(0)